Cancer Drug Annamycin Showed No Cardiac Toxicity
A new pooled analysis suggests this treatment option maintains heart function during cancer therapy.
Updated on Sept. 28, 2026 in Heart Disease
Live Poll
Does evidence of improved safety in drug trials increase your trust in new medical treatments?
A cardiac safety analysis published in Frontiers in Cardiovascular Medicine found no evidence of heart toxicity in patients treated with the cancer drug Annamycin. The findings, which offer hope for preserving heart health during cancer treatment, included data from 90 patients across five clinical trials.
Why it matters
Traditional anthracyclines are often restricted by dose-dependent heart damage, making drugs that avoid these side effects a significant focus of current research. This analysis provides early evidence that Annamycin may overcome this limitation for patients with acute myeloid leukemia and soft tissue sarcoma.
In a pooled analysis of 90 patients, including 78 with paired echocardiographic data, researchers found no statistically significant difference in cardiac function. The study, which included patients receiving a median cumulative dose of 660 mg/m², reported no evidence of cardiotoxicity via ECGs or biomarkers.
The players
Moleculin Biotech
A Houston-based pharmaceutical company focused on developing therapies for hematological malignancies and soft tissue sarcomas.
Cleveland Clinic
A major academic medical center that operates an independent cardio-oncology laboratory and provided the analysis of the study data.
The details
The analysis pooled data from clinical trials investigating Annamycin, an agent designed to avoid the cumulative, dose-dependent cardiotoxicity typically associated with traditional anthracyclines. Researchers at the Cleveland Clinic independently evaluated serial echocardiograms, global longitudinal strain assessments, and cardiac biomarkers to confirm that the drug did not negatively impact the left ventricular ejection fraction.
Timeline
September 28, 2026: Moleculin Biotech announced the publication of the cardiac safety findings.
Health Landscape
This report sits within the ongoing effort to develop cancer treatments that effectively target tumors while sparing the heart from damage. It provides a safety baseline for the drug's continued evaluation in the MIRACLE clinical development program.
Patients undergoing cancer treatment should discuss potential cardiotoxicity risks with their oncology team, especially if they have pre-existing heart conditions. Any questions regarding new drug safety or clinical trial eligibility should be addressed directly with your physician.
The takeaway
Maintaining heart health is a critical component of cancer care, and new drug safety data offers promise for future treatment options. Patients should track symptoms like shortness of breath or fatigue and review their cardiac monitoring plan with their care team.
Further reading
For more on managing heart health, visit Heart Disease.
Live Poll
Does evidence of improved safety in drug trials increase your trust in new medical treatments?
